Soleus Capital Management
ESPR icon

Soleus Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Soleus Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-6,700
Closed -$399K – 52
2019
Q4 		$399K Buy
+6,700
New +$301K 0.38% 40

Other funds holding ESPR

Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Credit Suisse
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Soleus Capital Management's ESPR Position: Q1 2020 in Review

Soleus Capital Management sold out of Esperion Therapeutics (ESPR) in Q1 2020, closing a stake of 6,700 shares — an estimated $399K sold.

Soleus Capital Management first reported a position in ESPR in Q4 2019 and held it in 1 quarter. The position peaked at $399K in Q4 2019. 166 funds tracked by Wall St. Rank hold ESPR as of Q1 2020.

  • Soleus Capital Management reported no remaining Esperion Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Soleus Capital Management sold 6,700 Esperion Therapeutics shares in Q1 2020, an estimated $399K.
  • Soleus Capital Management first reported a position in Esperion Therapeutics in Q4 2019 and held it in 1 quarter.
  • Soleus Capital Management's Esperion Therapeutics position peaked at $399K in Q4 2019.
  • 166 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2020.

Based on Soleus Capital Management's 13F filing for Q1 2020, filed 15 May 2020.